Document:

EX-10.28(vi)

 [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and
filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 
  

Exhibit 10.28(vi) 

AMENDMENT NO. 4 TO PROCESS DEVELOPMENT AND
CLINICAL SUPPLY AGREEMENT 
 THIS AMENDMENT
NO. 4 (the “Fourth Amendment”) is effective as of January 24, 2011 (the “Fourth Amendment Effective Date”) by and between Boehringer Ingelheim Pharma GmbH & Co. KG (“BI
Pharma”) and FibroGen, Inc. (“FibroGen”) amends the Process Development and Clinical Supply Agreement entered into by and between BI Pharma and FibroGen on November 29, 2007, as amended pursuant to the letter agreements
entered into as of on June 26, 2008 and August 18, 2008, the First Amendment on May 14, 2009 and the Third Amendment on November 5, 2010 (the “Supply Agreement”). BI Pharma and FibroGen shall be referred to individually
herein as a “Party”, and collectively as, the “Parties”. 
 WHEREAS, as
contemplated under Section 2.4 of the Supply Agreement, BI Pharma has conducted on behalf of FibroGen [ * ] using the Product [ * ], and the Process and the Product [ * ] have not been
materially changed; 
 WHEREAS, the Parties have agreed upon Specifications to which the Product must
be manufactured by BI Pharma, both for bulk drug substance and formulated drug product; and 
 WHEREAS, FibroGen
wishes to engage BI Pharma to conduct additional GMP runs, in compliance with the terms of the Supply Agreement. 
 NOW,
THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Parties agree as follows: 
  

	 	(1)	Unless otherwise defined herein, all capitalized terms and phrases used in this Fourth Amendment shall have the meaning ascribed to them in the Supply Agreement. 

 

	 	(2)	Pursuant to Section 2.2 of the Supply Agreement, the work plan entitled “[ * ]”, attached hereto as Exhibit A, is hereby added as an amendment to Appendix 2 to the Supply Agreement
BI Pharma, and pursuant thereto BI Pharma shall manufacture on behalf of FibroGen in accordance with the Supply Agreement, [ * ] and [ * ]. 

 

	 	(3)	The Specifications for the Product to be produced pursuant to Section 2 hereof have agreed to by the Parties and are set forth in the Amended and Restated Quality Agreement by and between the Parties, and are
hereby added as an amendment to Appendix 9 to the Supply Agreement, and shall apply to the activities contemplated by Section (2) above as part of the Acceptance Criteria for the Product. 

 

	 	(4)	This Fourth Amendment, together with the Supply Agreement, contains the entire understanding of the Parties with respect to the subject matter hereof. Except as otherwise provided herein, the Supply Agreement has not
been modified or amended and remains in full force and effect. All express or implied agreements and understandings that conflict with the terms of this Fourth Amendment, either oral or written, heretofore made with respect to subject matter herein
are expressly superseded by this Fourth Amendment. 

  
  

 

					
	 CONFIDENTIAL
	  	1	  	

	 	(5)	This Fourth Amendment may be executed in counterparts, each of which shall be deemed an original, and all of which together shall constitute one and the same instrument. Counterparts may be signed and delivered by
facsimile and/or via portable document format (pdf) (or similar format), each of which shall be binding when sent. 

 IN
WITNESS WHEREOF, the Parties have executed this Fourth Amendment to the Supply Agreement as of Fourth Amendment Effective Date. 
  

			
	FIBROGEN, INC.
		
	By:	 	 /s/ Michael Lowenstein

	Name:	 	 Michael Lowenstein

	Title:	 	 Legal Attorney

	Date:	 	 January 24, 2011

	
	BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG
	 ppa.

		
	By:	 	 [ * ]

	Name:	 	 [ * ]

	Title:	 	 VP Legal Germany

	Date:	 	 January 27, 2011

	
	BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG
	 ppa.

		
	By:	 	 [ * ]

	Name:	 	 [ * ]

	Title:	 	 VP Business & Contracts

	Date:	 	 January 28, 2011

  

					
	CONFIDENTIAL	 	2	 	

  
 [ * ] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 EXHIBIT A 

[ * ] 

  

					
	CONFIDENTIAL	 	3	 	

  
 [ * ] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.EX-10.28(vii)

 [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and
filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 
  

Exhibit 10.28(vii) 

AMENDMENT NO. 5 TO THE PROCESS DEVELOPMENT
AND CLINICAL SUPPLY AGREEMENT 
 THIS AMENDMENT
NO. 5 (the “Fifth Amendment”) is effective as of April 15, 2011 (the “Fifth Amendment Effective Date”) by and between Boehringer Ingelheim Pharma GmbH & Co. KG, Birkendorfer
Straße 65, 88397 Biberach an der Riss, Germany (“BI Pharma”) and FibroGen, Inc., 409 Illinois Street, San Francisco, CA 94158, USA (“FibroGen”) amends the Process Development and Clinical Supply Agreement entered
into by and between BI Pharma and FibroGen on November 29, 2007, as amended pursuant to the letter agreements entered into as of June 26, 2008 and August 18, 2008, the Amendment No. 1, effective as of May 28, 2009, the
Amendment No. 3, effective as of November 5, 2010, and the Amendment No. 4, effective as of January 24, 2011 (hereinafter together the “Supply Agreement”). BI Pharma and FibroGen shall be referred to individually herein
as a “Party”, and collectively as, the “Parties”. 
 WHEREAS, FibroGen wishes to engage BI Pharma to conduct
[ * ] as outlined in the Amendment No. 4, effective as of January 24, 2011. 
 NOW,
THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Parties agree as follows: 
  

	 	(1)	Unless otherwise defined herein, all capitalized terms and phrases used in this Fifth Amendment shall have the meaning ascribed to them in the Supply Agreement. 

 

	 	(2)	Pursuant to Section 2.2 of the Supply Agreement, the work plan entitled “[ * ] (Work scope and cost estimate, Version of March 16, 2011)”, attached hereto as Exhibit A, is
hereby added as an amendment to Appendix 2 to the Supply Agreement, and pursuant thereto BI Pharma shall [ * ] on behalf of FibroGen in accordance with the Supply Agreement. 

 

	 	(3)	This Fifth Amendment, together with the Supply Agreement, contains the entire understanding of the Parties with respect to the subject matter hereof. Except as otherwise provided herein, the Supply Agreement has not
been modified or amended and remains in full force and effect. All express or implied agreements and understandings that conflict with the terms of this Fifth Amendment, either oral or written, heretofore made with respect to subject matter herein
are expressly superseded by this Fifth Amendment. 

 (4) This Fifth Amendment may be executed in counterparts, each of which shall be deemed
an original, and all of which together shall constitute one and the same instrument. Counterparts may be signed and delivered by facsimile and/or via portable document format (pdf) (or similar format), each of which shall be binding when sent. 

IN WITNESS WHEREOF, the Parties have executed this Fifth Amendment to the Supply Agreement as of Fifth Amendment Effective Date. 

  
 1 

					
	Amendment No. 5 to the Process Development and Clinical Supply Agreement	  	 	Confidential	  

  

FIBROGEN, INC. 
  

			
	By:	 	    /s/ Jim Polarek

			
	Name:	 	 Jim Polarek

			
	Title:	 	   VP, Protein Therapeutics and Collagen Development

			
	Date:	 	   April 19, 2011

 BOEHRINGER INGELHEIM PHARMA GMBH & CO.
KG 
 Biberach, April 15, 2011 
  

					
		 	ppa.	    	ppa.
			
	By:	 	[ * ]	    	[ * ]
	Name:	 	[ * ]	    	[ * ]
	Title:	 	VP Business & Contracts	    	VP Legal Germany

 Exhibit: 
 Exhibit
A: Work scope and cost estimate (Version of March 16, 2011) 

  

					
		 	2	 	

  
 [ * ] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

					
	Amendment No. 5 to the Process Development and Clinical Supply Agreement	  	 	Confidential	  

  

Exhibit A 
 Work
scope and cost estimate 
 (Version of March 16, 2011) 

(3 pages) 
 [ * ] 

  

					
		 	3	 	

  
 [ * ] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.EX-10.28(viii)

 [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and
filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 
  

Exhibit 10.28(viii) 

AMENDMENT NO. 6 TO THE PROCESS DEVELOPMENT
AND CLINICAL SUPPLY AGREEMENT 
 THIS AMENDMENT
NO. 6 (the “Sixth Amendment”), effective as of May 26, 2011 (the “Sixth Amendment Effective Date”) by and between Boehringer Ingelheim Pharma GmbH & Co. KG, Birkendorfer Straße
65, 88397 Biberach an der Riss, Germany (“BI Pharma”) and FibroGen, Inc., 409 Illinois Street, San Francisco, CA 94158, USA (“FibroGen”), amends the Process Development and Clinical Supply Agreement entered into by and
between BI Pharma and FibroGen on November 29, 2007, as amended pursuant to the letter agreements entered into as of June 26, 2008 and August 18, 2008, Amendment No. 1, effective as of May 28, 2009, Amendment No. 3,
effective as of November 5, 2010, Amendment No. 4, effective as of January 24, 2011 (the “Fourth Amendment”), and Amendment No. 5, effective as of April 15, 2011 (hereinafter together the “Supply
Agreement”). BI Pharma and FibroGen shall be referred to individually herein as a “Party”, and collectively as, the “Parties”. 

WHEREAS, as contemplated under Section 2.4 of the Supply Agreement, BI Pharma has conducted on
behalf of FibroGen [ * ] using the Product [ * ], and the Process and the Product [ * ] have not been materially changed; 

WHEREAS, the Parties have agreed upon Specifications to which the Product must be manufactured by BI
Pharma, both for bulk drug substance and formulated drug product; and 
 WHEREAS, FibroGen wishes to engage BI Pharma
to conduct additional GMP runs and drug product fills, in compliance with the terms of the Supply Agreement. 
 NOW,
THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Parties agree as follows: 
  

	 	(1)	Unless otherwise defined herein, all capitalized terms and phrases used in this Sixth Amendment shall have the meaning ascribed to them in the Supply Agreement. 

 

	 	(2)	Pursuant to Section 2.2 of the Supply Agreement, the work plan entitled “[ * ] (Work Scope and Cost Estimate, Version of November 12, 2010)”, as attached to the Fourth Amendment is
hereby retroactively as of January 24, 2011 replaced in its entirety by the Work Scope and Cost Estimate, Version of May 24, 2011, which is attached hereto as Exhibit A and is hereby added as an amendment to Appendix 2 to the Supply
Agreement, and pursuant thereto BI Pharma shall [ * ] accordance with the Supply Agreement, [ * ] and [ * ] 

  

	 	(3)	The Specifications for the Product to be produced pursuant to Section 2 hereof have been agreed to by the Parties and are set forth in the Amended and Restated Quality Agreement by and between the Parties and shall
apply to the activities contemplated by Section (2) above as part of the Acceptance Criteria for the Product. 

  

	 	(4)	This Sixth Amendment, together with the Supply Agreement, contains the entire understanding of the Parties with respect to the subject matter hereof. Except as otherwise provided herein, the Supply Agreement has not
been modified or amended and remains in full force and effect. All express or implied agreements and understandings that conflict with the terms of this Sixth Amendment, either oral or written, heretofore made with respect to subject matter herein
are expressly superseded by this Sixth Amendment. 

  

					
	CONFIDENTIAL	 	1	 	

					
	Amendment No. 6 to the Process Development and Clinical Supply Agreement	  	 	Confidential	  

  
  

 

	 	(5)	This Sixth Amendment may be executed in counterparts, each of which shall be deemed an original, and all of which together shall constitute one and the same instrument. Counterparts may be signed and delivered by
facsimile and/or via portable document format (pdf) (or similar format), each of which shall be binding when sent. 

IN WITNESS WHEREOF, the Parties have executed this Sixth Amendment to the
Supply Agreement as of Sixth Amendment Effective Date. 
 Biberach, July 15, 2011 

BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG 

 

					
	i.V.	  		  	i.V.
			
	 [ * ]
	  		  	 [ * ]

	[ * ]	  		  	[ * ]
	Dir. Business and Contracts	  		  	Head of Team Biberach — Dep. Legal Germany

 San Francisco, July 18, 2011 
  

					
	FIBROGEN, INC	  		  	
			
	 /s/ Jim Polarek
	  		  	  

	 Name Jim Polarek
	  		  	 Name

	 Title: VP Protein Therapeutics and Collagen Development
	  		  	 Title

 Exhibit: 
 Exhibit
A: Work Scope and Cost Estimate (Version of May 24, 2011) 

  

					
	CONFIDENTIAL	 	2	 	

  
 [ * ] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

					
	Amendment No. 6 to the Process Development and Clinical Supply Agreement	  	 	Confidential	  

  
  

Exhibit A 
 Work
Scope and Cost Estimate 
 (Version of May 24, 2011) 

(4 pages) 
 [ * ] 

  

					
	CONFIDENTIAL	 	3	 	

  
 [ * ] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00236-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00236-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00236-of-00352.parquet"}]]